Intarcia Therapeutics Obtains $225,000,000 New Financing Round

  • Feed Type
  • Date
    4/28/2015
  • Company Name
    Intarcia Therapeutics
  • Mailing Address
    155 Seaport Boulevard 11th Floor Boston, MA 02210 USA
  • Company Description
    Intarcia Therapeutics Inc, a privately held pharmaceutical company, is developing therapies for the treatment of cancer, immunological, and infectious diseases.
  • Website
    http://www.intarcia.com
  • Transaction Type
    Debt
  • Transaction Amount
    $225,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies. In addition, proceeds from the financing will fund the expected infrastructure and talent required to launch ITCA 650 in the United States, and to advance the Company’s recently in-licensed pipeline assets.
  • M&A Terms
  • Venture Investor

Trending on Xconomy